Manulife (Manufacturers Life Insurance)’s Mineralys Therapeutics MLYS Stock Holding History

Manulife (Manufacturers Life Insurance)’s Portfolio MLYS Stock Details MLYS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$864K	Buy	32,007 +5,596	+21%	+$154K	﹤0.01%	2035
2026 Q1	$715K	Buy	26,411 +10,230	+63%	+$300K	﹤0.01%	1997
2025 Q4	$587K	Buy	16,181 +1,415	+10%	+$56.7K	﹤0.01%	2106
2025 Q3	$560K	Sell	14,766 -9	-0.1%	-$195	﹤0.01%	2161
2025 Q2	$200K	Buy	14,775 +3,390	+30%	+$49.1K	﹤0.01%	2562
2025 Q1	$181K	Sell	11,385 -412	-3%	-$4.74K	﹤0.01%	2524
2024 Q4	$145K	Sell	11,797 -347	-3%	-$4.54K	﹤0.01%	2727
2024 Q3	$147K	Sell	12,144 -288	-2%	-$3.49K	﹤0.01%	2765
2024 Q2	$145K	Buy	+12,432	New	+$157K	﹤0.01%	2716
2024 Q1	–	Sell	-11,514	Closed	-$99K	–	2979
2023 Q4	$99K	Buy	+11,514	New	+$90.4K	﹤0.01%	2823

Other funds holding MLYS

Catalys Pacific Tokyo, Japan $229M AUM 100.3% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Manulife (Manufacturers Life Insurance)'s MLYS Position: Q2 2026 in Review

Manulife (Manufacturers Life Insurance) increased its Mineralys Therapeutics (MLYS) stake by 21% in Q2 2026, buying an estimated $154K and bringing the position to 32,007 shares worth $864K. The position accounts for ﹤0.01% of the portfolio, ranked #2035.

Manulife (Manufacturers Life Insurance) first reported a position in MLYS in Q4 2023 and has held it in 10 quarters since. 224 funds tracked by Wall St. Rank hold MLYS as of Q2 2026.

Manulife (Manufacturers Life Insurance) held 32,007 shares of Mineralys Therapeutics worth $864K as of Q2 2026.
Manulife (Manufacturers Life Insurance) bought 5,596 Mineralys Therapeutics shares in Q2 2026, an estimated $154K.
Mineralys Therapeutics made up ﹤0.01% of Manulife (Manufacturers Life Insurance)'s portfolio in Q2 2026, its #2035 holding.
Manulife (Manufacturers Life Insurance) first reported a position in Mineralys Therapeutics in Q4 2023 and has held it in 10 quarters since.
224 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q2 2026.

Based on Manulife (Manufacturers Life Insurance)'s 13F filing for Q2 2026, filed 14 Aug 2026.